Eyepoint Pharmaceuticals (NASDAQ:EYPT) versus Celcuity (NASDAQ:CELC) Head-To-Head Analysis

Eyepoint Pharmaceuticals (NASDAQ:EYPT) and Celcuity (NASDAQ:CELC) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, risk, valuation, earnings, institutional ownership, analyst recommendations and profitability.

Profitability

This table compares Eyepoint Pharmaceuticals and Celcuity’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Eyepoint Pharmaceuticals	-3,566.63%	-110.54%	-90.15%
Celcuity	N/A	-244.61%	-50.22%

Risk & Volatility

Eyepoint Pharmaceuticals has a beta of 1.72, indicating that its share price is 72% more volatile than the S&P 500. Comparatively, Celcuity has a beta of 0.1, indicating that its share price is 90% less volatile than the S&P 500.

Institutional & Insider Ownership

99.4% of Eyepoint Pharmaceuticals shares are held by institutional investors. Comparatively, 63.3% of Celcuity shares are held by institutional investors. 5.1% of Eyepoint Pharmaceuticals shares are held by company insiders. Comparatively, 13.3% of Celcuity shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Eyepoint Pharmaceuticals and Celcuity”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eyepoint Pharmaceuticals	$31.37 million	36.29	-$231.96 million	($3.50)	-3.88
Celcuity	N/A	N/A	-$177.04 million	($3.90)	-34.07

Celcuity has lower revenue, but higher earnings than Eyepoint Pharmaceuticals. Celcuity is trading at a lower price-to-earnings ratio than Eyepoint Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Eyepoint Pharmaceuticals and Celcuity, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eyepoint Pharmaceuticals	1	0	4	2	3.00
Celcuity	1	0	11	0	2.83

Eyepoint Pharmaceuticals currently has a consensus price target of $31.80, suggesting a potential upside of 134.17%. Celcuity has a consensus price target of $150.27, suggesting a potential upside of 13.09%. Given Eyepoint Pharmaceuticals’ stronger consensus rating and higher probable upside, equities analysts clearly believe Eyepoint Pharmaceuticals is more favorable than Celcuity.

Summary

Eyepoint Pharmaceuticals beats Celcuity on 9 of the 14 factors compared between the two stocks.

About Eyepoint Pharmaceuticals

EyePoint Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is EYP-1901, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 2 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.

About Celcuity

Celcuity Inc., a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, advanced or metastatic breast cancer, and metastatic castration resistant prostate cancer. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. The company was founded in 2011 and is headquartered in Minneapolis, Minnesota.